Latest News

Biological Shuttle to the Brain


In this issue:

Getting the antibodies across the barrier A Roche study has given fresh impetus to an old dream. If researchers could safely and effectively breach the brain-blood barrier in humans, it would open up a huge number of options for hard-to-treat neurological diseases. As populations age, developing treatments for neurodegenerative disorders is growing increasingly critical - while the potential market for such therapies grows larger by the day. Is the cellular barrier that scientists have been chipping away at finally about to fall?

In this issue:

Getting the antibodies across the barrier A Roche study has given fresh impetus to an old dream. If researchers could safely and effectively breach the brain-blood barrier in humans, it would open up a huge number of options for hard-to-treat neurological diseases. As populations age, developing treatments for neurodegenerative disorders is growing increasingly critical - while the potential market for such therapies grows larger by the day. Is the cellular barrier that scientists have been chipping away at finally about to fall?

FAO presents food safety assessment on cell-based protein products

With more than 100 companies, including Israel's Aleph Farms, Holland's Mosa Meat and the UK's Higher Steaks Ltd., active in the future market of...

AI predicts an enzyme’s substrate

  Researchers from Germany, Sweden and India have reported an AI method that predicts whether an enzyme can work with a specific substrate. In...

Glioma drug combo turns tumours hot

Swiss researchers have shrinked one of the most lethal and untreatable types of cancer in mice using a combination treatment that proved safe in five...

EU to decarbonise aviation sector through green fuel targets

So far, SAF have been produced in tiny quantities and are far more expensive than kerosene.According to European Commissions draft regulation, fuel...

Researchers activate chemotherapeutics by ultrasound

Chemotherapeutic treatments produce strong side effects. A new drug complex that accumulates in the tumour tissue and is only activated there by...

Swiss Biotech Report: Sunrise, not sunset, is the feeling of the hour

The latest Swiss Biotech Report, published at the end of April by the Swiss Biotech Association (SBA) in collaboration with EY and eight other...

Cytovation ASA raises US$8m in Series A

A Series A follow-up financing of US$8m has brought up Cytovation ASA’s total Series A funding to US$28m. The Bergen-based company announced it will...